Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiang-Sha-Liu-Jun-Zi tang for semaglutide-induced gastrointestinal adverse effects in type 2 diabetes
ChiCTR2200058085Phase 4Not yet recruiting
- Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of Xiang Sha Liu Jun Zi Decoction and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hospital of Chengdu University of Traditional Chinese Medicine. Primary endpoints: Gastrointestinal Symptom Rating Scale and Duration of individual gastrointestinal adverse events. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Xiang Sha Liu Jun Zi Decoctionsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200058085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058085.